Recent studies have demonstrated that HSF1 expression is negatively correlated with immune checkpoint genes’ expression [38], tumor mutational burden (TMB), and microsatellite instability (MSI) in CRC [39], implying no reaction to immunotherapy when HSF1 is highly expressed. The gene discussed is HSF1; the disease is colorectal carcinoma.